We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Zomedica Pharmaceuticals Corp. (ZOM) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Zomedica Pharmaceuticals Corp. (ZOM - Free Report) closed the most recent trading day at $0.16, moving -0.3% from the previous trading session. This change lagged the S&P 500's 0.74% gain on the day. Meanwhile, the Dow gained 0.43%, and the Nasdaq, a tech-heavy index, added 1.67%.
Heading into today, shares of the company had lost 28.88% over the past month, lagging the Medical sector's gain of 3.64% and the S&P 500's gain of 5.51% in that time.
ZOM will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.01, up 50% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for ZOM. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ZOM is currently a Zacks Rank #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZOM in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Zomedica Pharmaceuticals Corp. (ZOM) Stock Sinks As Market Gains: What You Should Know
Zomedica Pharmaceuticals Corp. (ZOM - Free Report) closed the most recent trading day at $0.16, moving -0.3% from the previous trading session. This change lagged the S&P 500's 0.74% gain on the day. Meanwhile, the Dow gained 0.43%, and the Nasdaq, a tech-heavy index, added 1.67%.
Heading into today, shares of the company had lost 28.88% over the past month, lagging the Medical sector's gain of 3.64% and the S&P 500's gain of 5.51% in that time.
ZOM will be looking to display strength as it nears its next earnings release. The company is expected to report EPS of -$0.01, up 50% from the prior-year quarter.
It is also important to note the recent changes to analyst estimates for ZOM. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. ZOM is currently a Zacks Rank #2 (Buy).
The Medical - Drugs industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 104, which puts it in the top 41% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow ZOM in the coming trading sessions, be sure to utilize Zacks.com.